Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock

Key Points

• Halozyme Therapeutics CEO Helen Torley sold 20,000 shares of the company's stock for approximately $1.51 million, decreasing her ownership by 2.65% to 733,719 shares.
• The company's stock has experienced fluctuations, hitting a low of $42.01 and a high of $79.50 over the past year, recently trading down to $68.98.
• Halozyme reported strong quarterly earnings, exceeding expectations by posting $1.54 earnings per share and significant revenue growth of 40.8% year-over-year, leading to positive analyst ratings.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the completion of the sale, the chief executive officer owned 733,719 shares in the company, valued at $55,285,726.65. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Helen Torley also recently made the following trade(s):

• On Friday, October 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.03, for a total value of $1,380,600.00.
• On Wednesday, September 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $74.44, for a total value of $1,488,800.00.
• On Tuesday, August 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.51, for a total value of $1,270,200.00.
• On Wednesday, July 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO traded down $2.71 during midday trading on Friday, reaching $68.98. 2,656,731 shares of the company traded hands, compared to its average volume of 1,995,680. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $79.50. The stock has a 50-day moving average price of $70.23 and a 200 day moving average price of $61.92. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The company has a market cap of $8.07 billion, a price-to-earnings ratio of 15.78, a PEG ratio of 0.41 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. During the same period in the previous year, the business earned $0.91 earnings per share. The company's revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Halozyme Therapeutics

Institutional investors have recently bought and sold shares of the stock. Wealth Preservation Advisors LLC purchased a new position in Halozyme Therapeutics in the 1st quarter worth about $32,000. Newbridge Financial Services Group Inc. purchased a new position in Halozyme Therapeutics in the 2nd quarter worth about $32,000. SVB Wealth LLC purchased a new position in Halozyme Therapeutics in the 1st quarter worth about $33,000. Bessemer Group Inc. grew its stake in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares in the last quarter. Finally, Employees Retirement System of Texas purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $34,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of recent analyst reports. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $85.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday. Weiss Ratings restated a "hold (c+)" rating on shares of Halozyme Therapeutics in a research note on Saturday, September 27th. Zacks Research upgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 2nd. Wall Street Zen lowered Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. Finally, Benchmark lifted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $70.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.